Ultra Nasdaq Biotechnology Proshares (BIB) 153.74

New Post Public Reply Private Reply Replies (0) Message Board

Feb 28, 2015 at 7:31 PM

Ultra Nasdaq Biotechnology Proshares (BIB) 153.74 $BIB

Biotech selling off early
Seeking Alpha - at Seeking Alpha - Wed Feb 04, 9:04AM CST

BIB: 153.74 (-2.94), IBB: 337.47 (-3.33)

Ugly day for biotech
Seeking Alpha - at Seeking Alpha - Thu Jan 15, 1:03PM CST

BIB: 153.74 (-2.94), IBB: 337.47 (-3.33)

Biotech off to a good start on first trading day of 2015
Seeking Alpha - at Seeking Alpha - Fri Jan 02, 8:57AM CST

BIB: 153.74 (-2.94), IBB: 337.47 (-3.33)

Gilead, Abbvie, Express Scripts, And Biotech Industry Turmoil Seen By Market-Makers
Peter F. Way, CFA - Seeking Alpha - Wed Dec 24, 8:33AM CST
This is a market price forecast analysis It is not an analysis of medical technology, competition, or economics. We have limited competence in those areas. But we do have extensive experience in how market professionals have interpreted the likely...
ESRX: 84.79 (+0.25), GILD: 103.53 (-0.66), FBT: 115.23 (-0.93), BIB: 153.74 (-2.94), XBI: 214.63 (-3.26), IBB: 337.47 (-3.33), BBH: 127.98 (-1.22), ABBV: 60.50 (-0.02)

Look for Shares of ProShares Ultra Nasdaq Biotechnology ETF to Potentially Rebound after Yesterday's 9.20% Sell Off
Comtex SmarTrend(R) - Tue Dec 23, 5:13PM CST
ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB) traded in a range yesterday that spanned from a low of $116.34 to a high of $131.99. Yesterday, the shares fell 9.2%, which took the trading range below the 3-day low of $128.10 on volume of 948,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BIB: 153.74 (-2.94)

Money flowing out of biotech today
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 9:40AM CST

BIS: 36.39 (+0.66), ESRX: 84.79 (+0.25), GILD: 103.53 (-0.66), BIB: 153.74 (-2.94), IBB: 337.47 (-3.33), ABBV: 60.50 (-0.02)

ProShares Ultra Nasdaq Biotechnology ETF Has Returned 22.8% Since SmarTrend Recommendation (BIB)
Comtex SmarTrend(R) - Mon Dec 15, 9:19AM CST
SmarTrend identified an Uptrend for ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB) on October 21st, 2014 at $104.76. In approximately 2 months, ProShares Ultra Nasdaq Biotechnology ETF has returned 22.84% as of today's recent price of $128.68.
BIB: 153.74 (-2.94)

25.1% Return Seen to Date on SmarTrend ProShares Ultra Nasdaq Biotechnology ETF Call (BIB)
Comtex SmarTrend(R) - Fri Dec 05, 4:55PM CST
SmarTrend identified an Uptrend for ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB) on October 21st, 2014 at $104.76. In approximately 2 month, ProShares Ultra Nasdaq Biotechnology ETF has returned 25.05% as of today's recent price of $131.00.
BIB: 153.74 (-2.94)

Shares of BIB Up 23.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Nov 28, 11:03AM CST
SmarTrend identified an Uptrend for ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB) on October 21st, 2014 at $104.76. In approximately 1 month, ProShares Ultra Nasdaq Biotechnology ETF has returned 23.28% as of today's recent price of $129.14.
BIB: 153.74 (-2.94)

Vargatef cleared in Europe for lung cancer
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 8:23AM CST

HTBX: 6.66 (-0.16), BIB: 153.74 (-2.94), INCY: 85.85 (-1.69), PFE: 34.32 (-0.27), IBB: 337.47 (-3.33), DRGS: 58.85 (+0.05), BIND: 6.06 (-0.18), BMY: 60.92 (-0.54), GSK: 47.42 (-0.42), ONTY: 1.60 (-0.02), ECYT: 5.80 (-0.11), BIS: 36.39 (+0.66), CLVS: 76.46 (-1.43), AZN: 68.90 (-0.11), MRK: 58.54 (-0.42), ARIA: 8.13 (-0.04), IRY: 51.13 (+0.08), IXJ: 106.66 (-0.24), FPRX: 25.74 (-1.61)

UniQure sets price record with Glybera
Seeking Alpha - at Seeking Alpha - Wed Nov 26, 2:33PM CST

BIS: 36.39 (+0.66), QURE: 23.24 (+0.33), BIB: 153.74 (-2.94), ALXN: 180.37 (-2.74), IBB: 337.47 (-3.33)

China mulling eliminating drug price controls
Seeking Alpha - at Seeking Alpha - Wed Nov 26, 6:17AM CST

EWH: 21.71 (-0.03), PEK: 45.95 (-0.17), CNXT: 35.38 (+0.27), KBA: 46.58 (unch), BIB: 153.74 (-2.94), CQQQ: 35.81 (-0.28), IBB: 337.47 (-3.33), DRGS: 58.85 (+0.05), CHXF: 54.07 (+0.27), YINN: 40.58 (-0.04), FXP: 37.43 (-0.02), EWHS: 27.13 (-0.18), PGJ: 28.04 (-0.47), FCA: 23.73 (+0.10), YAO: 28.43 (-0.05), FCHI: 53.55 (-0.15), ASHR: 36.35 (-0.19), ASHS: 39.51 (unch), GXC: 82.10 (-0.20), FXI: 43.76 (-0.01), XPP: 76.05 (+0.01), KWEB: 32.43 (-0.52), ECNS: 45.05 (unch), TAO: 21.48 (-0.15), CHNA: 36.38 (-0.26), QQQC: 21.50 (-0.17), CHIX: 16.00 (unch), KFYP: 64.80 (unch), HAO: 25.89 (+0.09), MCHI: 53.06 (-0.02), CHIM: 15.39 (+0.14), YANG: 9.39 (+0.01), BIS: 36.39 (+0.66), CHIQ: 12.97 (-0.10), CHIE: 13.36 (+0.26), FHK: 41.14 (-0.14), CHII: 13.94 (-0.06), YXI: 26.75 (unch), CN: 35.33 (-0.20)

Drug makers face pushback on pricey meds
Seeking Alpha - at Seeking Alpha - Tue Nov 25, 7:18AM CST

ABT: 47.37 (-0.24), BIIB: 409.59 (-0.51), BIB: 153.74 (-2.94), PFE: 34.32 (-0.27), AMGN: 157.72 (-1.25), IBB: 337.47 (-3.33), LLY: 70.17 (+0.14), DRGS: 58.85 (+0.05), GSK: 47.42 (-0.42), BMY: 60.92 (-0.54), CELG: 121.53 (-1.82), JNJ: 102.51 (-0.29), ESRX: 84.79 (+0.25), BIS: 36.39 (+0.66), MRK: 58.54 (-0.42), AZN: 68.90 (-0.11), CVS: 103.87 (-0.30), ABBV: 60.50 (-0.02), SNY: 48.86 (-0.01), IRY: 51.13 (+0.08), IXJ: 106.66 (-0.24), NVS: 102.40 (-0.60)

Histogenics on deck for IPO
Seeking Alpha - at Seeking Alpha - Mon Nov 24, 3:30PM CST

IPO: 24.10 (-0.16), BIS: 36.39 (+0.66), BIB: 153.74 (-2.94), IBB: 337.47 (-3.33)

CB Pharma on deck for IPO
Seeking Alpha - at Seeking Alpha - Fri Nov 21, 10:46AM CST

IPO: 24.10 (-0.16), BIS: 36.39 (+0.66), BIB: 153.74 (-2.94), CNDO: 2.57 (-0.23), IBB: 337.47 (-3.33), DRGS: 58.85 (+0.05), IXJ: 106.66 (-0.24), IRY: 51.13 (+0.08)

CF Foundation sells royalties for $3.3B
Seeking Alpha - at Seeking Alpha - Thu Nov 20, 7:03AM CST

BIS: 36.39 (+0.66), VRTX: 119.43 (-0.54), BIB: 153.74 (-2.94), IBB: 337.47 (-3.33), DRGS: 58.85 (+0.05), IXJ: 106.66 (-0.24), IRY: 51.13 (+0.08)

Global drug tab will breach trillion dollar mark this year
Seeking Alpha - at Seeking Alpha - Thu Nov 20, 6:41AM CST

BIS: 36.39 (+0.66), IMS: 26.32 (-0.20), PCYC: 215.93 (-1.89), GILD: 103.53 (-0.66), BIB: 153.74 (-2.94), IBB: 337.47 (-3.33), AMGN: 157.72 (-1.25), DRGS: 58.85 (+0.05), IXJ: 106.66 (-0.24), IRY: 51.13 (+0.08)

Second Sight begins trading today
Seeking Alpha - at Seeking Alpha - Wed Nov 19, 8:42AM CST

IPO: 24.10 (-0.16), EYES: 16.17 (+4.37), BIS: 36.39 (+0.66), BIB: 153.74 (-2.94), IBB: 337.47 (-3.33)

Neothetics on deck for IPO
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 12:46PM CST

IPO: 24.10 (-0.16), BIS: 36.39 (+0.66), BIB: 153.74 (-2.94), IBB: 337.47 (-3.33)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Yeastar's AI Innovations Shine at Yeahs Awards 2026

Award Recap: The Best of Yeastar’s Yeahs 2026 Blasting out of the gates here with some hefty recognition at the Yeahs Awards 2026—Yeastar is slinging accolades like confetti at a wedding. What’s the deal? It’s all about their partners and their slick moves in Unified Communications (UC). These tech whizzes are racking up milestones in AI, cloud services, and...

Chemours Faces Securities Suit: What Investors Need to Know

Sparks Fly Between Chemours and Its Investors There ain't no rest for the weary, especially in the cutthroat world of stocks where one misstep can have ripple effects far and wide. Today, we're eyeballing The Chemours Company (NYSE: CC), sitting right in the bullseye as shareholders light the torches and march for justice. Class Action Suit: The Lay of the Land Alright...

Cerebras Faces Durability Allegations: Investor Alert

Cracks in Cerebras' Processor Promises? When you dance with high-stakes tech stocks, sometimes you end up stepping on a few toes. This seems to ring true as Cerebras Systems (CBRS) dances its way into hot water. Allegations from Culper Research suggest their fancy AI processors, which are supposed to be the poster children of reliability, might bow out early. Digging...

EDB Enhances Postgres with Horizontal Scaling Preview

EDB's Ambitious Move Into Seamless Data Growth Right out of Wilmington, Delaware, EnterpriseDB (EDB) is sowing the seeds for a seismic change in how enterprises juggle their data systems. With 86% of the top brass anticipating AI data systems becoming top-tier indispensable, the unveiling of EDB’s horizontal scaling for their Postgres AI Distributed is a tune you just...

Trump Quotation Book Takes Unbiased Approach

In the ever-evolving dance of political discourse, a new book strides onto the stage: Not My President, published by Palmetto Publishing. It’s a bold compilation of presidential utterances, capturing the words of Donald J. Trump in all their unvarnished glory. Stripped of analysis or comedic flair, each entry stands alone like a solitary figure at a cocktail party,...

Victory Gala Honors Heroes, Raises Over $500K

A Night Celebrating Service and Sacrifice You know, in times like these, it’s refreshing to see events that focus on giving back rather than taking everything to the bank. Victory Home Remodeling, along with its nonprofit arm, the Victory Foundation, recently hosted their second annual gala in Woodland Park, New Jersey to give some much-needed limelight to those who put...

MPLX Adds Industry Veterans to Board Leadership

A New Era for MPLX's Board Nothing shakes up the scene like announcing two heavyweights joining the board, and that's exactly what MPLX LP (NYSE: MPLX) just pulled off. Micheal G. Dunn and Bruce L. Niemeyer are coming onboard, effective November 1, 2026. With pedigrees that could make any industry insider nod in approval, these guys bring decades of experience to the...

RPC Reports Q3 Loss Amid Revenue Growth Quirks

RPC Rides Out a Rough Quarter with Strategic Moves Ah, the oilfield services game—never a dull moment, right? RPC, Inc. just dropped their Q3 2026 results, and there’s a mixed bag to digest here. On the one hand, they saw a modest 1% uptick in revenue, hitting $467.7 million. But on the flip side, they're grappling with a hefty net loss of $41.9 million thanks to a...

Shield HealthCare Expands Access for Astiva Members

Opening Up New Avenues for Health Care Here's a nugget from the healthcare sector that's worth chewing on. Shield HealthCare has just inked a deal with Astiva Health that opens the floodgates for eligible members in Southern California to access medical supplies through Shield's extensive network. It's a big move that aims to make health management a tad easier for folks...

Hanwha's Big Bet: Tokenizing Real-World Assets with Chainlink

Hanwha and Chainlink: A Game Changer in Tokenization What do Hanwha Investment & Securities, a heavyweight in Korea's finance scene, and Chainlink, the wizard of onchain finance, think they're up to? They're buddies now, locked and loaded, to tokenize real-world assets (RWAs). They're not just shaking hands; they're aiming to jiggle the global finance bedrock....